Skip to main content

Advertisement

SpringerLink
Log in

Acetylation Pharmacogenetics and Renal Function in Diabetes Mellitus Patients

  • Original Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Activities of human hepatic drug metabolizing enzymes N-acetyl transferase (NATS) had earlier been recognized as a cause of inter-individual variation in the metabolism of drugs. Therefore acetylation of many drugs in human exhibit genetic polymorphism. The aim of the study was to investigate if acetylator status predispose diabetic mellitus patients more to the complications of renal disease, One hundred and twenty (120) diabetics consisting of (50) Type 1 (T1) and 70 Type 2 (T2) diabetes mellitus patients and 100 healthy individuals as controls were classified as slow or rapid acetylator using sulphamethazine (SMZ) as an in vivo probe. The percentage acetylation, recovery of SMZ, creatinine clearance and presence of urinary albumin were determined. A significant difference (P < 0.05) was observed in the percentage of SMZ acetylated between slow and rapid acetylators in control, T1 and T2 subjects. The ratios of slow to rapid acetylators for T1, T2 and control subjects were 1:4, 3:2 and 2:3 respectively. No significant differences were observed in the percentage of SMZ recovered in the urine of slow and rapid acetylators that are diabetics. The difference in creatinine clearance of slow and rapid acetylators in T1 and T2 were significant (P < 0.05). 29% out of 120 (24.2%) diabetics (T1 and T2) exhibited albuminuria out of which 25 (86.2%) had slow acetylator status. These findings suggest that slow acetylator status in diabetes mellitus could be a predisposing factor in the development of renal complications. This underscores the need for a rapid pharmacogenetic testing and therapeutic drug monitoring in such patients. However this inference could be further validated with a larger sample size.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Shenfield GM. Genetic polymorphisms, drug metabolism and drug concentrations. Clin Biochem Rev. 2004;Nov:203–6.

    Google Scholar 

  2. Meyer VA. Pharmacogenetics and adverse drug reactions. Lancet. 2000;356:1667–71.

    Article  CAS  PubMed  Google Scholar 

  3. Stephanovic M, Topic E, Simundic AM. Novel SSCP method for molecular diagnostics of thiopurine S-methyltransferase (TPMP) deficiencies. Clin Chem Lab Med 2004;42(9):A94.

    Google Scholar 

  4. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta. 1988;948:37–66.

    CAS  PubMed  Google Scholar 

  5. Okumura K, Kita T, Chikazewa S, Komada F, Iwakawa S, Tanigawa Y. Genotyping of N-acetylator polymorphism and correlation with procainamide metabolism. Clin Pharmacol Ther. 1997;61:509–17.

    Article  CAS  PubMed  Google Scholar 

  6. Evans DA. Ethnic differences in reactions to drugs and xenobiotics, acetylation. Prog Clin Biol Res. 1986;214:209–42.

    CAS  PubMed  Google Scholar 

  7. El Desoky ES, Abdel Salam YM, Salama RH, El AKkad MA, Atanasova S, Von Ahsen N, et al. NAT 2*5/*5 genotype (341T<C) is a potential risk factor for schistosomiasis-associated bladder cancer in Egyptians. Ther Drug Monit. 2005;27(3):297–304.

    Article  CAS  PubMed  Google Scholar 

  8. Woolhouse WM, Qureshi MM, Bastaki SMA, Patel M, Abdulrazzaq Y, Bayoumi RAL. Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis. Pharmacogenetics. 1997;7:73–82.

    Article  CAS  PubMed  Google Scholar 

  9. Ait Moussa L, Khassouani CE, Hue B, Jana M, Begaud B, Soulaymani R. Determination of the acetylator phenotype in Moroccan tuberculosis patients using isoniazid as metabolic probe. Crit Care Med. 2002;30:2107–14.

    Article  Google Scholar 

  10. Cranswick N, Mulholland K. Isoniazid treatment of children: can genetics help guide treatment? Arch Dis Child. 2005;90:551–3.

    Article  CAS  PubMed  Google Scholar 

  11. Fawcett IW, Gammon PT. The determination of acetylator phenotype in a Nigerian population. Tubercle. 1975;5:199–201.

    Article  Google Scholar 

  12. Eze LC, Obidoa AO. Acetylator of SMZ in a Nigerian population. Biochem Genet. 1978;16:1073–7.

    Article  CAS  PubMed  Google Scholar 

  13. Jeyakumar LH, French MR. Polymorphic acetylation of sulphamethazine in a Nigerian (Yoruba) population. Xenobiotica. 1981;11:319–21.

    Article  CAS  PubMed  Google Scholar 

  14. Delaney MP, Price CP, Lamb EJ. Kidney function and disease. In: Burtis CA, Ashwood ER, Burns DE, editors. Tiez fundamentals of clinical chemistry. 6th ed. St. Louis, Missouri: Saunders, Elsevier; 2008. p. 638–9.

    Google Scholar 

  15. Evans DA, White TA. Human acetylation polymorphism. J Lab Clin Med. 1964;63:394–403.

    CAS  PubMed  Google Scholar 

  16. Tucker G. Pharmacogenetics—expectations and reality. Editorial. Br Med J. 2004;329:4–5.

    Article  Google Scholar 

  17. Bunn HF. Evaluation of glycosylated haemoglobin in diabetic patients. Diabetes. 1981;30:613–7.

    CAS  PubMed  Google Scholar 

  18. Evans WE. Pharmacogenetics of thiopurine S-methyl transferase and thiopurine. Ther Drug Monit. 2004;26:186–9.

    Article  CAS  PubMed  Google Scholar 

  19. McLaren EH, Burden AC, Moorhead PJ. Acetylator phenotype in diabetic neuropathy. Br Med J. 1977;2:291–3.

    Article  CAS  PubMed  Google Scholar 

  20. Summer Scales JE, Josephy PD. Human acetyl-COA: arylamine N-acetyl transferase variants generated random mutagenesis. Mol Pharmacol. 2004;65:220–6.

    Article  CAS  Google Scholar 

  21. Shenfield GM, Gross AS. The cytochrome p450 system and adverse drug reactions. Adv Drug React Bull. 1999;194:739–42.

    Article  Google Scholar 

  22. Chang JB, Anderson RC, Cruz PD. Steven-Johnson syndrome associated with glipizide therapy. Dermatitis. 2006;17(1):36–8.

    Google Scholar 

  23. Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP 2C9 gene. Eur J Clin Investig. 2003;33(Suppl 2):23–30.

    Article  CAS  Google Scholar 

  24. Grant DM, Morike K, Eichelbaum M, Mayer UA. Acetylation, pharmacogenetics; the slow acetylators phenotype is caused by decreased or absent arylamine N-acetyl transferase in human liver. J Clin Investig. 1990;85(3):968–72.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemical Pathology, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria

    S. O. Banjoko

  2. Department of Chemical Pathology, College of Medicine, University College Hospital, Ibadan, Nigeria

    K. S. Akinlade

Authors
  1. S. O. Banjoko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. S. Akinlade
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. O. Banjoko.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Banjoko, S.O., Akinlade, K.S. Acetylation Pharmacogenetics and Renal Function in Diabetes Mellitus Patients. Indian J Clin Biochem 25, 289–294 (2010). https://doi.org/10.1007/s12291-010-0055-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-010-0055-5

Keywords

Search

Navigation